ATE434447T1 - Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion - Google Patents

Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion

Info

Publication number
ATE434447T1
ATE434447T1 AT99972110T AT99972110T ATE434447T1 AT E434447 T1 ATE434447 T1 AT E434447T1 AT 99972110 T AT99972110 T AT 99972110T AT 99972110 T AT99972110 T AT 99972110T AT E434447 T1 ATE434447 T1 AT E434447T1
Authority
AT
Austria
Prior art keywords
compositions
methods
vessel occlusion
producing vessel
administering
Prior art date
Application number
AT99972110T
Other languages
English (en)
Inventor
Michael Stewart
Roland Person
Antoine Noujaim
Original Assignee
Novolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novolytics Inc filed Critical Novolytics Inc
Application granted granted Critical
Publication of ATE434447T1 publication Critical patent/ATE434447T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT99972110T 1998-11-12 1999-11-10 Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion ATE434447T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10812998P 1998-11-12 1998-11-12
PCT/IB1999/001809 WO2000029029A1 (en) 1998-11-12 1999-11-10 Compositions and methods for producing vascular occlusion

Publications (1)

Publication Number Publication Date
ATE434447T1 true ATE434447T1 (de) 2009-07-15

Family

ID=22320484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972110T ATE434447T1 (de) 1998-11-12 1999-11-10 Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion

Country Status (10)

Country Link
US (4) US6887474B1 (de)
EP (1) EP1131106B1 (de)
JP (1) JP2002529521A (de)
AT (1) ATE434447T1 (de)
AU (1) AU773174B2 (de)
CA (1) CA2348781A1 (de)
DE (1) DE69941031D1 (de)
IL (2) IL142864A0 (de)
RU (1) RU2227752C2 (de)
WO (1) WO2000029029A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
EP1098665B9 (de) * 1998-07-13 2003-08-13 The Board Of Regents, The University Of Texas System Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
RU2227752C2 (ru) * 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
EP1051116B8 (de) 1998-12-01 2009-06-10 Washington University Vorrichtung zur intravaskulären embolisierung
JP2005511502A (ja) * 2001-09-12 2005-04-28 ヴィレックス リサーチ インコーポレイテッド 固定化した血小板結合剤を有する血管閉塞固相剤
TW200303919A (en) 2001-12-05 2003-09-16 Hiroyuki Ohno Cytotoxic protein and the use
AU2002365844A1 (en) * 2001-12-07 2003-06-17 Antoine Noujaim Compositions and methods for producing vascular occlusion
JP5183010B2 (ja) 2002-05-16 2013-04-17 グリコミメティクス， インコーポレイテッド セレクチンによって媒介される機能を阻害するための化合物および方法
US20040180812A1 (en) * 2002-12-13 2004-09-16 Technology Center Methods of treating and preventing proliferative disease
FR2851211B1 (fr) 2003-02-19 2006-01-13 Faurecia Sieges Automobile Siege rabattable et vehicule comportant un tel siege
ATE383367T1 (de) 2003-11-19 2008-01-15 Glycomimetics Inc Spezifischer antagonist sowohl für e- als auch p- selektine
US20060009496A1 (en) * 2004-06-15 2006-01-12 Oates John A Method for preventing hemoprotein and heme-mediated lipid peroxidation
US9155764B1 (en) 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
PT1819230E (pt) 2004-12-07 2012-08-07 Univ Miami Micropartículas derivadas de células vermelhas como agentes hemostáticos para o controlo da hemorragia e para o tratamento de patologias hemorrágicas
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
ES2375979T3 (es) 2005-08-09 2012-03-07 Glycomimetics, Inc. Inhibidores glicomiméticos de la lectina pa-il, lectina pa-iil o ambas lectinas de pseudomonas.
DK2264043T3 (da) 2005-09-02 2018-01-29 Glycomimetics Inc Heterobifunktionelle pan-selektin-inhibitorer
US20070178104A1 (en) * 2006-01-31 2007-08-02 Awdalla Essam T Methods and means for treating solid tumors
US9307995B2 (en) * 2006-06-15 2016-04-12 Cook Medical Technologies Llc Methods, systems and devices for the delivery of endoluminal prostheses
CA2666103C (en) 2006-10-12 2014-02-18 Glycomimetics, Inc. Glycomimetic replacements for hexoses and n-acetyl hexosamines
US7879793B2 (en) 2006-10-18 2011-02-01 Baylor College Of Medicine Treatment of medical condition with A2 domain of von willebrand factor
CA2677747A1 (en) 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
US8372427B2 (en) * 2007-03-05 2013-02-12 Abbott Cardiovascular Systems Inc. Therapeutic composition with enhanced endothelium targeting
US8039442B2 (en) 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US8617820B2 (en) * 2007-08-28 2013-12-31 Ortho-Clinical Diagnostics, Inc. Use of glycosaminoglycans to reduce non-specific binding in immunoassays
US8029560B2 (en) 2007-09-12 2011-10-04 Cook Medical Technologies Llc Enhanced remodelable materials for occluding bodily vessels
US20110135736A1 (en) * 2007-11-26 2011-06-09 Stewart Michael W Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent
JP5471447B2 (ja) * 2007-12-25 2014-04-16 国立大学法人山口大学 薬物送達システム
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
CN102088983B (zh) 2008-06-13 2013-01-30 糖模拟物有限公司 利用选择的糖模拟化合物的血液癌症的治疗
US10421819B2 (en) * 2008-10-06 2019-09-24 Minerva Biotechnologies Corporation MUC1* antibodies
EP2418956A4 (de) * 2009-04-17 2013-04-03 Niiki Pharma Inc Verfahren zur behandlung von hepatozellulärem karzinom
JP5726171B2 (ja) 2009-05-01 2015-05-27 グリコミメティックス インコーポレイテッド Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
US9044454B2 (en) * 2010-03-10 2015-06-02 Northwestern University Regulation of microvasculature occlusion
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
CN103957903A (zh) * 2011-09-15 2014-07-30 翁特拉制药公司 用于治疗、逆转、抑制或预防对抗血小板治疗的耐受性的方法和组合物
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
LT2928476T (lt) 2012-12-07 2018-05-25 Glycomimetics, Inc. Junginiai, kompozicijos ir būdai, naudojant e-selektino antagonistus, hemopoetinių ląstelių mobilizacijai
KR101552138B1 (ko) * 2012-12-26 2015-09-10 국립암센터 신규한 암 병변 표지용 조성물
WO2015154057A1 (en) * 2014-04-04 2015-10-08 Nhan Tran Methods for treating cancer
CA2957552C (en) * 2014-08-08 2024-01-16 Vindico Nanobiotechnology, Llc Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors
PL3227310T3 (pl) 2014-12-03 2020-02-28 Glycomimetics, Inc. Heterodwufunkcyjne inhibitory selektyn E i receptorów chemokinowych CXCR4”
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
CA3009836A1 (en) 2016-01-22 2017-07-27 Glycomimetics, Inc. Glycomimetic inhibitors of pa-il and pa-iil lectins
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
ES2865481T3 (es) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
JP2019524791A (ja) 2016-08-08 2019-09-05 グリコミメティクス， インコーポレイテッド Ｅ−セレクチンの阻害剤もしくはｃｘｃｒ４の阻害剤との、またはｅ−セレクチンおよびｃｘｃｒ４両方のヘテロ二機能性阻害剤とのｔ細胞チェックポイント阻害剤の組み合わせ
CN109890421B (zh) 2016-10-07 2023-10-20 糖模拟物有限公司 高效的多聚体e-选择蛋白拮抗剂
RU2768743C2 (ru) 2016-11-30 2022-03-24 Юниверсити Оф Майами Композиция на основе rmp и способы ее применения
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11712418B2 (en) 2017-05-26 2023-08-01 Bruin Biosciences, Inc. Chemoembolization agents
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
EP3732186A1 (de) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunktionale inhibitoren von e-selektin und galectin-3
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
CA2194369C (en) * 1994-07-11 2004-08-31 Philip E. Thorpe Methods and compositions for the specific coagulation of vasculature
US5763199A (en) * 1994-09-29 1998-06-09 Mount Sinai School Of Medicine Of The City University Of New York Platelet blockade assay
JPH08333400A (ja) * 1995-06-09 1996-12-17 Ajinomoto Co Inc 抗血栓活性を有する融合蛋白質及びその製法
US6218513B1 (en) * 1995-12-22 2001-04-17 Baxter Biotech Technology Sarl Globins containing binding domains
IL130908A0 (en) * 1997-01-22 2001-01-28 Univ Texas Tissue-factor (tf) compositions for coagulation and tumor treatment
RU2227752C2 (ru) * 1998-11-12 2004-04-27 Новолитикс Инк. Способы перекрытия кровотока и композиции для их реализации
JP2005511502A (ja) * 2001-09-12 2005-04-28 ヴィレックス リサーチ インコーポレイテッド 固定化した血小板結合剤を有する血管閉塞固相剤

Also Published As

Publication number Publication date
US7947282B2 (en) 2011-05-24
EP1131106B1 (de) 2009-06-24
IL142864A (en) 2007-09-20
AU1171600A (en) 2000-06-05
CA2348781A1 (en) 2000-05-25
JP2002529521A (ja) 2002-09-10
US6887474B1 (en) 2005-05-03
IL142864A0 (en) 2002-03-10
US20070098724A1 (en) 2007-05-03
EP1131106A1 (de) 2001-09-12
WO2000029029A9 (en) 2000-11-02
RU2227752C2 (ru) 2004-04-27
US7390488B2 (en) 2008-06-24
WO2000029029A1 (en) 2000-05-25
US20020168366A1 (en) 2002-11-14
DE69941031D1 (de) 2009-08-06
AU773174B2 (en) 2004-05-20
US20050287145A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
ATE434447T1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
HU9700084D0 (en) Composition for specific coagulating vascular system
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
ATE222488T1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
MXPA03009408A (es) Factor de crecimiento endotelial vascular 2.
PT1782825E (pt) Tratamento de doenças de armazenanto de glicogénio tipo ii
PT998287E (pt) Utilizacao de levobupivacaina
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
PL327542A1 (en) Agents capable to bond hialuronic acid receptors and their application
DE60330501D1 (de) Verfahren zur behandlung von verletzungen des nervensystems in verbindung mit einer blutung
EP1240900A4 (de) Medizinische zusammensetzungen zur prävention und behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
DE50108711D1 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
MXPA02000052A (es) Metodos y composiciones para el soporte, regeneracion y reparacion de tejidos conectivos.
DE69926357D1 (de) Vorbereitung eines medikaments zur behandlung von refluxösophagitis
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
ATE272651T1 (de) Verbindungen mit wachstumshormon-freisetzender eigenschaft
UA29106A (uk) Спосіб лікування вібраційної хвороби

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties